A detailed history of Concourse Financial Group Securities, Inc. transactions in Genmab A/S stock. As of the latest transaction made, Concourse Financial Group Securities, Inc. holds 388 shares of GMAB stock, worth $8,012. This represents 0.0% of its overall portfolio holdings.

Number of Shares
388
Previous 504 23.02%
Holding current value
$8,012
Previous $12,000 25.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

SELL
$23.84 - $28.48 $2,765 - $3,303
-116 Reduced 23.02%
388 $9,000
Q2 2024

Jul 23, 2024

BUY
$25.13 - $30.27 $1,331 - $1,604
53 Added 11.75%
504 $12,000
Q1 2024

Apr 30, 2024

SELL
$26.43 - $32.77 $1,057 - $1,310
-40 Reduced 8.15%
451 $13,000
Q4 2023

Feb 07, 2024

SELL
$27.94 - $35.44 $2,179 - $2,764
-78 Reduced 13.71%
491 $15,000
Q3 2023

Oct 25, 2023

BUY
$35.27 - $42.24 $16,294 - $19,514
462 Added 431.78%
569 $20,000
Q2 2023

Aug 10, 2023

BUY
$37.4 - $42.94 $785 - $901
21 Added 24.42%
107 $4,000
Q1 2023

May 15, 2023

SELL
$34.88 - $43.22 $837 - $1,037
-24 Reduced 21.82%
86 $3,000
Q3 2022

Nov 15, 2022

SELL
$31.52 - $373.61 $1,103 - $13,076
-35 Reduced 24.14%
110 $4,000
Q2 2022

Aug 09, 2022

BUY
$26.83 - $38.57 $2,307 - $3,317
86 Added 145.76%
145 $5,000
Q4 2021

Feb 07, 2022

BUY
$35.87 - $47.12 $753 - $989
21 Added 55.26%
59 $2,000
Q4 2020

Feb 02, 2021

SELL
$33.66 - $40.76 $1,750 - $2,119
-52 Reduced 57.78%
38 $2,000
Q3 2020

Nov 13, 2020

BUY
$33.07 - $38.68 $595 - $696
18 Added 25.0%
90 $3,000
Q2 2020

Aug 13, 2020

SELL
$20.05 - $33.89 $340 - $576
-17 Reduced 19.1%
72 $2,000
Q1 2020

May 13, 2020

SELL
$17.15 - $25.22 $3,344 - $4,917
-195 Reduced 68.66%
89 $2,000
Q3 2019

Nov 13, 2019

BUY
$18.0 - $21.38 $5,112 - $6,071
284 New
284 $6,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.6B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.